Loxo Oncology Company Profile (NASDAQ:LOXO)

About Loxo Oncology

Loxo Oncology logoLoxo Oncology, Inc. is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer. Its pipeline includes LOXO-101, LOXO-195, Rearranged During Transfection (RET) Program and Fibroblast Growth Factor Receptor (FGFR) program. LOXO-101 is a selective inhibitor of tropomyosin receptor kinases (TRK) for the treatment of patients with soft tissue sarcoma. LOXO-195 is a selective TRK inhibitor capable of addressing potential mechanisms of acquired resistance that may emerge in patients receiving LOXO-101 or multikinase inhibitors with anti-TRK activity. It has designed a series of RET inhibitors that optimize on-target potency for RET gene fusions, mutations and clinically-identified resistance mutations. It is designing FGFR1-sparing FGFR inhibitor.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: LOXO
  • CUSIP:
Key Metrics:
  • Previous Close: $41.66
  • 50 Day Moving Average: $39.39
  • 200 Day Moving Average: $29.41
  • 52-Week Range: $16.50 - $44.95
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.27
  • P/E Growth: 0.00
  • Market Cap: $910.91M
  • Outstanding Shares: 21,678,000
  • Beta: 2.95
Profitability:
  • Return on Equity: -37.23%
  • Return on Assets: -36.17%
Debt:
  • Current Ratio: 24.00%
  • Quick Ratio: 24.00%
Additional Links:
Companies Related to Loxo Oncology:

Analyst Ratings

Consensus Ratings for Loxo Oncology (NASDAQ:LOXO) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $40.00 (4.81% downside)

Analysts' Ratings History for Loxo Oncology (NASDAQ:LOXO)
Show:
DateFirmActionRatingPrice TargetDetails
2/8/2017Jefferies Group LLCInitiated CoverageBuy$50.00View Rating Details
1/6/2017BTIG ResearchInitiated CoverageBuyView Rating Details
12/21/2016Cowen and CompanyReiterated RatingOutperformView Rating Details
12/20/2016Citigroup Inc.Set Price TargetBuy$44.00View Rating Details
4/19/2016Oppenheimer Holdings, Inc.Reiterated RatingOutperform$30.00View Rating Details
4/18/2016Stifel NicolausReiterated RatingBuy$36.00View Rating Details
11/11/2015JMP SecuritiesBoost Price Target$26.00 -> $29.00View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Loxo Oncology (NASDAQ:LOXO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
11/2/2016Q316($0.74)($0.82)ViewN/AView Earnings Details
5/4/2016Q1($0.69)($0.59)ViewN/AView Earnings Details
3/15/2016Q4($0.53)($0.73)ViewN/AView Earnings Details
11/10/2015Q3($0.53)($0.53)ViewN/AView Earnings Details
8/5/2015Q215($0.45)($0.49)ViewListenView Earnings Details
5/14/2015Q1($0.50)($0.38)ViewN/AView Earnings Details
11/14/2014Q314($0.37)($0.68)ViewN/AView Earnings Details
9/12/2014($12.27)($14.46)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Loxo Oncology (NASDAQ:LOXO)
Current Year EPS Consensus Estimate: $-3.06 EPS
Next Year EPS Consensus Estimate: $-3.73 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.77)($0.49)($0.63)
Q2 20161($0.61)($0.61)($0.61)
Q3 20161($0.63)($0.63)($0.63)
Q4 20162($0.82)($0.65)($0.74)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Loxo Oncology (NASDAQ:LOXO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Loxo Oncology (NASDAQ:LOXO)
Insider Ownership Percentage: 44.40%
Institutional Ownership Percentage: 82.44%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/10/2017Aisling Capital Iii LpMajor ShareholderBuy160,000$31.00$4,960,000.00View SEC Filing  
12/19/2016Keith T FlahertyDirectorSell7,250$30.23$219,167.50View SEC Filing  
9/7/2016Keith T FlahertyDirectorSell14,500$30.00$435,000.00View SEC Filing  
8/11/2016Keith T FlahertyDirectorSell15,000$26.00$390,000.00View SEC Filing  
8/10/2016David P BonitaDirectorSell447,857$26.96$12,074,224.72View SEC Filing  
5/17/2016Aisling Capital Iii LpMajor ShareholderBuy232,558$21.50$4,999,997.00View SEC Filing  
11/17/2015Avi Z NaiderDirectorBuy3,773$26.50$99,984.50View SEC Filing  
11/13/2015Aisling Capital Iii LpMajor ShareholderBuy78,669$27.65$2,175,197.85View SEC Filing  
8/6/2014James E FlynnInsiderBuy1,089,656$13.01$14,176,424.56View SEC Filing  
8/6/2014Orbimed Advisors LlcMajor ShareholderBuy275,385$13.00$3,580,005.00View SEC Filing  
8/6/2014Steve ElmsDirectorBuy413,077$13.00$5,370,001.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Loxo Oncology (NASDAQ:LOXO)
DateHeadline
News IconStock Watch: Focusing in on Loxo Oncology, Inc. (NASDAQ:LOXO) - Baldwin Journal (NASDAQ:LOXO)
baldwinjournal.com - February 22 at 11:31 PM
streetinsider.com logoLoxo Oncology (LOXO) Completes Trial Enrollment for Larotrectinib NDA Primary Efficacy Analysis (NASDAQ:LOXO)
www.streetinsider.com - February 22 at 6:31 PM
News IconInvestor Investigation over Potential Wrongdoing at Loxo Oncology Inc (NASDAQ:LOXO) - Digital Journal (NASDAQ:LOXO)
www.digitaljournal.com - February 21 at 6:40 PM
streetinsider.com logoLoxo Oncology (LOXO) Completes Trial Enrollment for Larotrectinib NDA Primary Efficacy Analysis - StreetInsider.com (NASDAQ:LOXO)
www.streetinsider.com - February 21 at 6:40 PM
finance.yahoo.com logoLoxo Oncology Announces Completion of Clinical Trial Enrollment for Larotrectinib NDA Primary Efficacy Analysis (NASDAQ:LOXO)
finance.yahoo.com - February 21 at 6:40 PM
sbwire.com logoInvestor Investigation over Potential Wrongdoing at Loxo Oncology Inc (NASDAQ:LOXO) (NASDAQ:LOXO)
www.sbwire.com - February 20 at 5:44 PM
News IconCantor Fitzgerald Analysts Give Array BioPharma Inc. (ARRY) a $13.00 Price Target (NASDAQ:LOXO)
ibusinesslines.com - February 17 at 6:25 PM
News IconArray Biopharma Inc (NASDAQ:ARRY) 2Q2017 Revenue Surpass Consensus (NASDAQ:LOXO)
www.financialstrend.com - February 17 at 6:25 PM
News IconIs The Sell-Side Predicting That Loxo Oncology, Inc. (NASDAQ:LOXO) Will Move Higher? - Winfield Review (NASDAQ:LOXO)
winfieldreview.com - February 17 at 1:25 PM
News IconLoxo Oncology, Inc. (LOXO) Under Analyst Spotlight - UK Market News (NASDAQ:LOXO)
www.ukmarketnews.co.uk - February 17 at 1:25 PM
seekingalpha.com logoArray BioPharma's (ARRY) CEO Ron Squarer on Q2 2017 Results - Earnings Call Transcript (NASDAQ:LOXO)
seekingalpha.com - February 9 at 7:18 PM
News IconArray BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2017 (NASDAQ:LOXO)
www.bio-medicine.org - February 9 at 7:18 PM
News IconLoxo Oncology Inc (LOXO) is Initiated by Jefferies to “Buy” - Highland Mirror (NASDAQ:LOXO)
www.highlandmirror.com - February 9 at 5:08 AM
4-traders.com logoDepartment of Industry and Science Australian Go : Grants help more Australians celebrate National Science Week (NASDAQ:LOXO)
www.4-traders.com - February 8 at 7:07 PM
finance.yahoo.com logoCoverage initiated on Loxo Oncology by Jefferies (NASDAQ:LOXO)
finance.yahoo.com - February 8 at 7:07 PM
finance.yahoo.com logoPurcell Julie & Lefkowitz LLP is Investigating Loxo Oncology, Inc. for Potential Breaches of Fiduciary Duty by its Board of Directors (NASDAQ:LOXO)
finance.yahoo.com - February 8 at 7:07 PM
News IconWhat is Recommendation from Analysts on Clovis Oncology Inc (NASDAQ:CLVS)? (NASDAQ:LOXO)
mlbinjurynews.com - February 7 at 7:38 PM
sbwire.com logoInsights of Salivary Gland Cancer Pipeline Review H2 2016 and Therapeutic Development (NASDAQ:LOXO)
www.sbwire.com - February 2 at 12:10 AM
News IconAre Analysts Forecasting a Near-Term Upswing For Loxo Oncology, Inc. (NASDAQ:LOXO)? - Wall Street Beacon (NASDAQ:LOXO)
wsbeacon.com - February 1 at 7:10 PM
News IconStocks Wilt on Friday But Pull Off Positive Week, How Did This One Fare: Loxo Oncology, Inc. (NASDAQ:LOXO) - Wall Street Beacon (NASDAQ:LOXO)
wsbeacon.com - January 29 at 11:40 PM
News IconTechnical Updates on Shares of Loxo Oncology Inc. (LOXO) - Rives Journal (NASDAQ:LOXO)
rivesjournal.com - January 29 at 6:38 PM
News IconTrading Sheet: Tracking Technicals for Loxo Oncology Inc. (LOXO) - Market Point (NASDAQ:LOXO)
mtptnews.com - January 28 at 4:09 AM
News IconEarnings in Full Force, Analysts Take Aim at Loxo Oncology, Inc. (NASDAQ:LOXO) - Wall Street Beacon (NASDAQ:LOXO)
wsbeacon.com - January 28 at 4:09 AM
News IconIndicators in Focus on Loxo Oncology, Inc. (NASDAQ:LOXO) - The Tribune (NASDAQ:LOXO)
lakecitytribune.com - January 25 at 7:45 PM
News IconExpanded Access to Provide Larotrectinib (LOXO-101) for the Treatment of Cancers With a NTRK Gene Fusion (NASDAQ:LOXO)
satprnews.com - January 22 at 6:11 PM
News IconHere's Who Just Picked Up Loxo Oncology Inc. (NASDAQ:LOXO ... - Small Cap Exclusive (press release) (NASDAQ:LOXO)
smallcapexclusive.com - January 19 at 8:12 PM
reuters.com logoBRIEF-Access Industries Management LLC reports 8.15 pct stake in Loxo Oncology as of Jan 10 - SEC Filing (NASDAQ:LOXO)
www.reuters.com - January 18 at 11:53 PM
investornewswire.com logoLoxo Oncology, Inc. (NASDAQ:LOXO) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:LOXO)
www.investornewswire.com - January 18 at 6:51 PM
News IconTrading Views: RSI, MA, and ADX Review for Loxo Oncology Inc. (LOXO) - Springdale Times (NASDAQ:LOXO)
springdaletimes.com - January 18 at 6:51 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on Loxo Oncology, Inc. (NASDAQ:LOXO) - Wall Street Beacon (NASDAQ:LOXO)
wsbeacon.com - January 18 at 6:51 PM
News IconPrice Action Alert: Loxo Oncology Inc's Trend Up, Especially After Today's All Time High Milestone - Fair View Times (NASDAQ:LOXO)
fairviewtimes.com - January 17 at 6:43 PM
investornewswire.com logoLoxo Oncology, Inc. (NASDAQ:LOXO) Records An Impact Score Of 0 - Investor Newswire (NASDAQ:LOXO)
www.investornewswire.com - January 16 at 8:25 AM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Loxo ... - Wall Street Beacon (NASDAQ:LOXO)
wsbeacon.com - January 16 at 8:25 AM
News IconWill The Needle Move For Loxo Oncology, Inc. (NASDAQ:LOXO) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:LOXO)
wsbeacon.com - January 14 at 5:38 AM
News IconThe Scotts Miracle-Gro Company Announces Commencement of Exchange Offer for ... (NASDAQ:LOXO)
www.econotimes.com - January 11 at 6:59 PM
globenewswire.com logoLoxo Oncology Announces the Closing of its Follow-On Offering of Common Stock and Full Exercise of the ... - GlobeNewswire (press release) (NASDAQ:LOXO)
globenewswire.com - January 11 at 5:20 AM
finance.yahoo.com logoLoxo Oncology Announces the Closing of its Follow-On Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares (NASDAQ:LOXO)
finance.yahoo.com - January 10 at 7:14 PM
marketexclusive.com logoLOXO ONCOLOGY,INC. (NASDAQ:LOXO) Files An 8-K Entry into a Material Definitive Agreement - Market Exclusive (NASDAQ:LOXO)
marketexclusive.com - January 10 at 6:21 AM
us.rd.yahoo.com logoOne of The Largest Hedge Funds In The World Is Betting On Loxo Oncology Inc. (LOXO) (NASDAQ:LOXO)
us.rd.yahoo.com - January 9 at 7:07 PM
insidermonkey.com logoOne of The Largest Hedge Funds In The World Is Betting On Loxo Oncology Inc. (NASDAQ:LOXO) (NASDAQ:LOXO)
www.insidermonkey.com - January 8 at 6:03 PM
einnews.com logo20 Best-Selling Cars of 2016 (NASDAQ:LOXO)
brazilbusiness.einnews.com - January 7 at 12:01 AM
News IconThat's a 'Loxo' cash: $120M offering to accelerate larotrectinib prospects (NASDAQ:LOXO)
www.bioworld.com - January 7 at 12:01 AM
marketexclusive.com logoAnalyst Activity – BTIG Research Initiates Coverage On Loxo Oncology (NASDAQ:LOXO) With a Buy (NASDAQ:LOXO)
marketexclusive.com - January 7 at 12:01 AM
finance.yahoo.com logo6:46 am Loxo Oncology prices 3.87 mln common stock offering at $31.00/share (NASDAQ:LOXO)
finance.yahoo.com - January 5 at 7:45 PM
publicnow.com logoLoxo Oncology Prices Follow-On Offering of Common Stock (NASDAQ:LOXO)
www.publicnow.com - January 5 at 7:45 PM
biz.yahoo.com logoLOXO ONCOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Financi (NASDAQ:LOXO)
biz.yahoo.com - January 5 at 7:45 PM
streetinsider.com logoLoxo Oncology (LOXO) to Offers Shares of Common Stock (NASDAQ:LOXO)
www.streetinsider.com - January 5 at 5:14 AM
reuters.com logoBRIEF-Loxo Oncology announces offering of common stock (NASDAQ:LOXO)
www.reuters.com - January 4 at 7:10 PM
4-traders.com logoMonday Sector Leaders: Drugs, Communicationss Services (NASDAQ:LOXO)
www.4-traders.com - December 21 at 7:37 AM
smarteranalyst.com logoThis Top Analyst Cheers Loxo Oncology Inc (LOXO) Clinical Progress as Shares Soar 26% (NASDAQ:LOXO)
www.smarteranalyst.com - December 21 at 7:37 AM

Social

What is Loxo Oncology's stock symbol?

Loxo Oncology trades on the NASDAQ under the ticker symbol "LOXO."

Where is Loxo Oncology's stock going? Where will Loxo Oncology's stock price be in 2017?

6 analysts have issued 1-year price objectives for Loxo Oncology's shares. Their predictions range from $30.00 to $50.00. On average, they expect Loxo Oncology's stock price to reach $40.00 in the next twelve months.

When will Loxo Oncology announce their earnings?

Loxo Oncology is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

Who owns Loxo Oncology stock?

Loxo Oncology's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), Access Industries Management, LLC (8.15%), Orbimed Advisors LLC (7.97%), Adage Capital Partners, LP (5.28%), Paulson & CO. Inc. (3.82%) and Eventide Asset Management LLC (3.41%). Company insiders that own Loxo Oncology stock include Aisling Capital Iii Lp, Avi Z Naider, David P Bonita and Keith T Flaherty.

Who sold Loxo Oncology stock? Who is selling Loxo Oncology stock?

Loxo Oncology's stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC and Metropolitan Life Insurance Co. NY. Company insiders that have sold Loxo Oncology stock in the last year include David P Bonita and Keith T Flaherty.

Who bought Loxo Oncology stock? Who is buying Loxo Oncology stock?

Loxo Oncology's stock was bought by a variety of institutional investors in the last quarter, including Paulson & CO. Inc., Russell Investments Group Ltd., Opaleye Management Inc., Partners Group Holding AG, Trexquant Investment LP, BP PLC, State Street Corp and FMR LLC. Company insiders that have bought Loxo Oncology stock in the last two years include Aisling Capital Iii Lp and Avi Z Naider.

How do I buy Loxo Oncology stock?

Shares of Loxo Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Loxo Oncology stock cost?

One share of Loxo Oncology stock can currently be purchased for approximately $42.02.

Loxo Oncology (NASDAQ:LOXO) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Earnings History Chart

Earnings by Quarter for Loxo Oncology (NASDAQ:LOXO)

Dividend History Chart

Dividend Payments by Quarter for Loxo Oncology (NASDAQ:LOXO)

Last Updated on 2/23/2017 by MarketBeat.com Staff